Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.

ABSTRACT: Discovery of therapeutic antibodies is a field of intense development, where immunization of rodents remains a major source of antibody candidates. However, high orthologue protein sequence homology between human and rodent species disfavors generation of antibodies against functionally conserved binding epitopes. Chickens are phylogenetically distant from mammals. Since chickens generate antibodies from a restricted set of germline genes, the possibility of adapting the Symplex antibody discovery platform to chicken immunoglobulin genes and combining it with high-throughput humanization of antibody frameworks by "mass complementarity-determining region grafting" was explored. Hence, wild type chickens were immunized with an immune checkpoint inhibitor programmed cell death 1 (PD1) antigen

SUBMITTER: Gjetting T 

PROVIDER: S-EPMC6601539 | biostudies-literature | 2019 May/Jun

REPOSITORIES: biostudies-literature